RC1416

Phase 2Small molecule

NNanjing RegeneCore Biotech Co., Ltd.

RC1416 is one of 24 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

Chronic Obstructive Pulmonary Disease (COPD)Recruiting

AsthmaPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary Disease (COPD)Phase 2

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Formoterol Fumarate

AstraZeneca

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

RC1416

NNanjing RegeneCore Biotech Co., Ltd.

Phase 2

1 8

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Asthma

NCT07403487

Q3 2028

Phase 2Recruiting

Chronic Obstructive Pulmonary Disease (COPD)

NCT07402551

Clinical

Trials by Indication[1]

Phase IB1 trial

A Phase Ib Study of RC1416 Injection

Completed·NNanjing RegeneCore Biotech Co., Ltd.·Phase 1·NCT06911866·40 enrolled

Asthma1 trial

Phase II Trial of RC1416 Injection in Asthma

Not yet recruiting·NNanjing RegeneCore Biotech Co., Ltd.·Phase 2·NCT07403487·195 enrolled

C141 trial

A Phase I Study of RC1416 Injection

Completed·NNanjing RegeneCore Biotech Co., Ltd.·Phase 1·NCT06067490·48 enrolled

Chronic Obstructive Pulmonary Disease (COPD)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Recruiting·NNanjing RegeneCore Biotech Co., Ltd.·Phase 2·NCT07402551·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RC1416. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RC1416 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RC1416. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing RegeneCore Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNanjing RegeneCore Biotech Co., Ltd.

RC1416

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Phase IB1 trial

Asthma1 trial

C141 trial

Chronic Obstructive Pulmonary Disease (COPD)1 trial

References

Drug Info

Quick Facts

Related News